Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY:
Biologic agents represent the next evolution in treatment for the primary systemic vasculitides. Greater understanding of these diseases has allowed us to move further away from nonspecific, highly toxic therapies toward a more directed approach. As our experience with these agents increases, they will likely form the keystone of treatment in the near future.
|
Authors | Sharon A Chung, Philip Seo |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 21
Issue 1
Pg. 3-9
(Jan 2009)
ISSN: 1531-6963 [Electronic] United States |
PMID | 19077713
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Biological Products
- Immunoglobulins, Intravenous
- Immunologic Factors
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
- Rituximab
|
Topics |
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Biological Products
(pharmacology, therapeutic use)
- Clinical Trials as Topic
(trends)
- Humans
- Immunoglobulins, Intravenous
(pharmacology, therapeutic use)
- Immunologic Factors
(pharmacology, therapeutic use)
- Immunosuppression Therapy
(methods, trends)
- Immunosuppressive Agents
(pharmacology, therapeutic use)
- Rituximab
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, physiology)
- Vasculitis
(drug therapy, immunology, physiopathology)
|